Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2612]

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib analysis of beamion LUNG-1

WCLC 2024: Zongertinib demonstrates promising efficacy in patients with HER2-mutant NSCLC: Primary phase Ib...

WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients with HER2-mutant NSCLC

WCLC 2024: Breakthrough therapy BAY 2927088 demonstrates ‘rapid, substantial and durable responses’ in patients...

WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients with NSCLC with EGFR PACC mutations

WCLC 2024: Results from the FURTHER trial demonstrate firmonertinib is a promising potential therapy for patients...

WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer

WCLC 2024: Amivantamab-vmjw plus lazertinib show strong favourable overall survival trend versus osimertinib in...

WCLC 2024: Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data releases at IASLC 2024 World Conference on Lung Cancer

WCLC 2024: Artificial intelligence method transforms gene mutation prediction in lung cancer: DeepGEM data...

WCLC 2024: Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer

WCLC 2024: Antibody–drug conjugate I-DXd shows clinically meaningful response in patients with extensive-stage...

WCLC 2024: IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer biomarker testing

WCLC 2024: IASLC Global Survey on biomarker testing reveals progress and persistent barriers in lung cancer...

WCLC 2024: Research shows pathway to developing predictive biomarkers for immune checkpoint inhibitors

WCLC 2024: Research shows pathway to developing predictive biomarkers for immune checkpoint inhibitors

WCLC 2024: Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive advanced NSCLC in HARMONi-2 study

WCLC 2024: Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive...

WCLC 2024: Normalised membrane ratio of TROP2 by quantitative continuous scoring predictive of clinical outcomes in TROPION-Lung 01

WCLC 2024: Normalised membrane ratio of TROP2 by quantitative continuous scoring predictive of clinical outcomes...

More from ecancer